Menu Menu


GLAXF Financials       Clear


GLAXF        0001131399    
Filing Date Form Type Description Document
2025-11-06 6-K TRANSACTION IN OWN SHARES View Document
2025-11-05 6-K TRANSACTION IN OWN SHARES View Document
2025-11-04 6-K TRANSACTION IN OWN SHARES View Document
2025-11-03 6-K TOTAL VOTING RIGHTS View Document
2025-11-03 6-K TRANSACTION IN OWN SHARES View Document
2025-10-31 6-K TRANSACTION IN OWN SHARES View Document
2025-10-30 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-10-30 6-K TRANSACTION IN OWN SHARES View Document
2025-10-29 6-K TRANSACTION IN OWN SHARES View Document
2025-10-29 6-K 3RD QUARTER RESULTS View Document
2025-10-28 6-K TRANSACTION IN OWN SHARES View Document
2025-10-28 6-K GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EU View Document
2025-10-27 6-K TRANSACTION IN OWN SHARES View Document
2025-10-24 6-K BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA View Document
2025-10-24 6-K TRANSACTION IN OWN SHARES View Document
2025-10-23 6-K TRANSACTION IN OWN SHARES View Document
2025-10-22 6-K POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDI View Document
2025-10-22 6-K TRANSACTION IN OWN SHARES View Document
2025-10-22 6-K LATOZINEMAB DATA READ OUT View Document
2025-10-21 6-K POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFS View Document
2025-10-21 6-K TRANSACTION IN OWN SHARES View Document
2025-10-21 6-K GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBR View Document
2025-10-20 6-K TRANSACTION IN OWN SHARES View Document
2025-10-17 6-K TRANSACTION IN OWN SHARES View Document
2025-10-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-10-16 6-K TRANSACTION IN OWN SHARES View Document
2025-10-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-10-15 6-K TRANSACTION IN OWN SHARES View Document
2025-10-14 6-K GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINA View Document
2025-10-14 6-K TRANSACTION IN OWN SHARES View Document
2025-10-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-10-14 6-K TRANSACTION IN OWN SHARES View Document
2025-10-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-10-10 6-K TRANSACTION IN OWN SHARES View Document
2025-10-09 6-K TRANSACTION IN OWN SHARES View Document
2025-10-08 6-K TRANSACTION IN OWN SHARES View Document
2025-10-07 6-K TRANSACTION IN OWN SHARES View Document
2025-10-06 6-K TRANSACTION IN OWN SHARES View Document
2025-10-03 6-K TRANSACTION IN OWN SHARES View Document
2025-10-02 6-K TRANSACTION IN OWN SHARES View Document
2025-10-01 6-K TOTAL VOTING RIGHTS View Document
2025-10-01 6-K TRANSACTION IN OWN SHARES View Document
2025-09-30 6-K GSK - THIRD TRANCHE OF SHARE BUYBACK PROGRAMME View Document
2025-09-29 6-K GSK APPOINTS CEO DESIGNATE View Document
2025-09-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-09-19 6-K TRANSACTION IN OWN SHARES View Document
2025-09-18 6-K TRANSACTION IN OWN SHARES View Document
2025-09-17 6-K GSK US INVESTMENT ANNOUNCEMENT View Document
2025-09-17 6-K TRANSACTION IN OWN SHARES View Document
2025-09-16 6-K TRANSACTION IN OWN SHARES View Document
2025-09-15 6-K TRANSACTION IN OWN SHARES View Document
2025-09-12 6-K TRANSACTION IN OWN SHARES View Document
2025-09-11 6-K TRANSACTION IN OWN SHARES View Document
2025-09-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-09-10 6-K TRANSACTION IN OWN SHARES View Document
2025-09-09 6-K TRANSACTION IN OWN SHARES View Document
2025-09-08 6-K TRANSACTION IN OWN SHARES View Document
2025-09-05 6-K TRANSACTION IN OWN SHARES View Document
2025-09-04 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-09-04 6-K TRANSACTION IN OWN SHARES View Document
2025-09-03 6-K TRANSACTION IN OWN SHARES View Document
2025-09-02 6-K TRANSACTION IN OWN SHARES View Document
2025-09-02 6-K TOTAL VOTING RIGHTS View Document
2025-09-02 6-K TRANSACTION IN OWN SHARES View Document
2025-08-29 6-K TRANSACTION IN OWN SHARES View Document
2025-08-28 6-K TRANSACTION IN OWN SHARES View Document
2025-08-27 6-K TRANSACTION IN OWN SHARES View Document
2025-08-26 6-K TRANSACTION IN OWN SHARES View Document
2025-08-22 6-K TRANSACTION IN OWN SHARES View Document
2025-08-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-08-21 6-K TRANSACTION IN OWN SHARES View Document
2025-08-20 6-K TRANSACTION IN OWN SHARES View Document
2025-08-19 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-08-19 6-K TRANSACTION IN OWN SHARES View Document
2025-08-18 6-K TRANSACTION IN OWN SHARES View Document
2025-08-15 6-K TRANSACTION IN OWN SHARES View Document
2025-08-14 6-K TRANSACTION IN OWN SHARES View Document
2025-08-13 SCHEDULE 13D View Document
2025-08-13 6-K TRANSACTION IN OWN SHARES View Document
2025-08-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-08-12 6-K TRANSACTION IN OWN SHARES View Document
2025-08-11 6-K FDA TO REVIEW GONORRHEA INDICATION FOR GEPOTIDACIN View Document
2025-08-11 6-K TRANSACTION IN OWN SHARES View Document
2025-08-08 6-K CUREVAC/BIONTECH MRNA PATENT LITIGATION SETTLEMENT View Document
2025-08-08 6-K TRANSACTION IN OWN SHARES View Document
2025-08-07 6-K TRANSACTION IN OWN SHARES View Document
2025-08-06 6-K TRANSACTION IN OWN SHARES View Document
2025-08-05 6-K TRANSACTION IN OWN SHARES View Document
2025-08-04 6-K TRANSACTION IN OWN SHARES View Document
2025-08-01 6-K TOTAL VOTING RIGHTS View Document
2025-08-01 6-K TRANSACTION IN OWN SHARES View Document
2025-07-31 6-K TRANSACTION IN OWN SHARES View Document
2025-07-30 6-K 2ND QUARTER RESULTS View Document
2025-07-30 6-K TRANSACTION IN OWN SHARES View Document
2025-07-29 6-K TRANSACTION IN OWN SHARES View Document
2025-07-28 6-K GSK ENTERS HENGRUI PHARMA COLLABORATION AGREEMENTS View Document
2025-07-28 6-K PRIMARY DOCUMENT View Document
2025-07-25 6-K TRANSACTION IN OWN SHARES View Document
2025-07-24 6-K BLENREP APPROVED IN THE EU FOR MULTIPLE MYELOMA View Document
2025-07-24 6-K TRANSACTION IN OWN SHARES View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299